The global incidence of tuberculosis (TB) infection was estimated by the WHO to be 10 million cases in 2018, 85% of whom had pulmonary TB (pTB) infection (WHO 2019). In Europe, the extrapulmonary TB (EPTB) incidence is increasing, accounting for 22.6% of new cases reported in 2017 (ECDC 2019). Furthermore, the incidence of articular TB infections has risen in Europe (Jutte 2004, Lesic 2010. This is reflected in UK surveillance data, where in 2017, 2.2% of new TB cases presented with non-spinal bone infections (Kruijshaar 2009, PHE 2018. Globally, this rise in EPTB infections has largely been ascribed to a growing population of immunosuppressed patients including those on long-term steroids and biologic therapies, as well as to an ageing population (Pigrau-Serrallach 2013, Byng-Maddick 2016). However, in low-incidence countries in Europe the rise in articular TB infections has also been attributed to increasing rates of migration (Jutte 2004, Krujishaar 2009. EPTB infection is thought to occur through haematogenous, contiguous or lymphatic spread in the primary infection stage, when mycobacteria can spread to any organ or tissue and remain dormant for years. Articular infection most commonly affects weight-bearing large joints such as the spine, knees and hips. Infection is often slowly progressing with joint effusions and pain, progressing to the formation of sinus tracts and eventually to complete joint destruction (Hogan 2017). Initial symptoms are vague and may mimic other conditions such as bacterial osteoarticular infection. This can result in significant diagnostic delay, especially in settings where TB is non-endemic and clinical suspicion is low (Erdem 2005, Broderick 2018). Most studies describing osteoarticular TB have focused on paediatric populations or on spinal TB with only a few published case series of extra-